CoChat

Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications

Open access
Moretto, Roberto, Elliott, Andrew, Zhang, Jian, Arai, Hiroyuki, Germani, Marco Maria, Conca, Veronica, Xiu, Joanne, Stafford, Phillip, Oberley, Matthew, Abraham, Jim, Spetzler, David, Rossini, Daniele, Antoniotti, Carlotta, Marshall, John, Shields, Anthony, Lopes, Gilberto, Lonardi, Sara, Pietrantonio, Filippo, Tomasello, Gianluca, Passardi, Alessandro, Tamburini, Emiliano, Santini, Daniele, Aprile, Giuseppe, Masi, Gianluca, Falcone, Alfredo, Lenz, Heinz-Josef, Korn, Michael, Cremolini, Chiara · 2022 · JNCI: Journal of the National Cancer Institute
Cited by 77

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Background: Tumors with homologous recombination deficiency (HRD) show high sensitivity to platinum salts and poly(ADP-ribose) polymerase–inhibitors in several malignancies. In colorectal cancer (CRC), the role of HRD alterations is mostly unknown. Methods: Next-generation sequencing, whole transcriptome sequencing, and whole exome sequencing were conducted using CRC samples submitted to a commercial Clinical Laboratory Improvement Amendments certified laboratory. Tumors with pathogenic and/or presumed pathogenic mutations in 33 genes involved in the homologous recombination pathway were considered HRD, the others were homologous recombination proficient (HRP). Furthermore, tumor samples from patients enrolled in the phase III TRIBE2 study comparing upfront FOLFOXIRI+bevacizumab vs FOLFOX+bevacizumab were analyzed with next-generation sequencing. The analyses were separately conducted in microsatellite stable or proficient mismatch repair (MSS/pMMR) and microsatellite instable-high or deficient mismatch repair (MSI-H/dMMR) groups. All statistical tests were 2-sided. Results: Of 9321 CRC tumors, 1270 (13.6%) and 8051 (86.4%) were HRD and HRP, respectively. HRD tumors were more frequent among MSI-H/dMMR than MSS/pMMR tumors (73.4% vs 9.5%; P < .001; q < 0.001). In MSS/pMMR group, HRD tumors were more frequently tumor mutational burden high (8.1% vs 2.2%; P < .001; q < 0.001) and PD-L1 positive (5.0% vs 2.4%; P < .001; q = 0.001), enriched in all immune cell and fibroblast populations and genomic loss of heterozygosity-high (16.2% vs 9.5%; P = .03). In the TRIBE2 study, patients with MSS/pMMR and HRD tumors (10.7%) showed longer overall survival compared with MSS/pMMR and HRP tumors (40.2 vs 23.8 months; hazard ratio [HR] = 0.66, 95% confidence interval [CI] = 0.45 to 0.98; P = .04). Consistent results were reported in the multivariable model (HR = 0.67, 95% CI = 0.45 to 1.02; P = .07). No interaction effect was evident between homologous recombination groups and treatment arm. Conclusions: HRD tumors are a distinctive subgroup of MSS/pMMR CRCs with specific molecular and prognostic characteristics. The potential efficacy of agents targeting the homologous recombination system and immune checkpoint inhibitors in this subgroup is worthy of clinical investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djab169

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 77

Metadata

Authors
Moretto, R., Elliott, A., Zhang, J., Arai, H., Germani, M. M., Conca, V., Xiu, J., Stafford, P., Oberley, M., Abraham, J., Spetzler, D., Rossini, D., Antoniotti, C., Marshall, J., Shields, A., Lopes, G., Lonardi, S., Pietrantonio, F., Tomasello, G., Passardi, A., Tamburini, E., Santini, D., Aprile, G., Masi, G., Falcone, A., Lenz, H.-J., Korn, M., & Cremolini, C.
Venue
JNCI: Journal of the National Cancer Institute
Published
2021-09-01
Volume
114
Issue
2
Pages
271-279
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W3197532732
Cited by
77
References
15
FWCI
7.31
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. https://app.cochat.ai/papers/10.1093/jnci/djab169
The paper
Moretto, R., Elliott, A., Zhang, J., Arai, H., Germani, M. M., Conca, V., Xiu, J., Stafford, P., Oberley, M., Abraham, J., Spetzler, D., Rossini, D., Antoniotti, C., Marshall, J., Shields, A., Lopes, G., Lonardi, S., Pietrantonio, F., Tomasello, G., . . . Cremolini, C. (2022). Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djab169

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.